Beximco Pharmaceuticals (DHA:BXPHARMA) ROCE % : 15.04% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Beximco Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beximco Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2023 was 15.04%.

Beximco Pharmaceuticals ROCE % Historical Data

The historical data trend for Beximco Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals ROCE % Chart

Beximco Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

13.93

14.99

17.59

15.81

13.38

Beximco Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															16.16	14.46	11.21	11.34	15.04

Beximco Pharmaceuticals ROCE % Calculation

Beximco Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	7310.429	/	( ( (66148.036 - 12735.932)	+	(69156.783 - 13265.024) )	/ 2 )
	=	7310.429	/	( (53412.104	+	55891.759)	/ 2 )
	=	7310.429	/	54651.9315
	=	13.38 %

Beximco Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	8492.24	/	( ( (69156.783 - 13265.024)	+	(70626.673 - 13600.66) )	/ 2 )
	=	8492.24	/	( ( 55891.759	+	57026.013 )	/ 2 )
	=	8492.24	/	56458.886
	=	15.04 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Beximco Pharmaceuticals (DHA:BXPHARMA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beximco Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (DHA:BXPHARMA) » Definitions » ROCE %

Traded in Other Exchanges

BXP:UK R2WA:Germany

Address

19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205

Website

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.

Beximco Pharmaceuticals (DHA:BXPHARMA) Headlines

No Headlines